S-1: Plus Therapeutics Launches $14.3M Offering Amidst Nasdaq Scrutiny

Plus Therapeutics, a radiotherapeutics and diagnostics company, is launching a public offering of units and pre-funded units to raise capital, while navigating ongoing Nasdaq listing compliance challenges and advancing its cancer treatment pipeline.

Summary

• Plus Therapeutics is offering 22,321,429 units, each consisting of one share of common stock and one warrant, at an assumed public offering price of $0.56 per unit.
• An additional 22,321,429 pre-funded units are offered for purchasers exceeding beneficial ownership limits, with each pre-funded unit consisting of one pre-funded warrant and one warrant, priced at $0.56 minus $0.001.
• The company expects to receive net proceeds of approximately $10.9 million from this offering, or $12.7 million if the underwriter's over-allotment option is fully exercised.
• As of September 30, 2025, the company reported an accumulated deficit of $510.2 million and used $14.5 million in net cash for operating activities during the nine months ended September 30, 2025.
• The company faces substantial doubt about its ability to continue as a going concern due to recurring losses and negative cash flows.
• Plus Therapeutics is not in compliance with Nasdaq's Minimum Bid Requirement ($1.00 per share) since May 16, 2025, with an extended compliance period until May 11, 2026, and may consider a reverse stock split.
• The company regained compliance with Nasdaq's Minimum Stockholders Equity Requirement in March and August 2025 but remains under a one-year monitoring period until August 22, 2026.
• REYOBIQ, a lead radiotherapeutic candidate for CNS cancers, has completed Phase 1 of the ReSPECT-GBM trial, with Phase 2 enrollment targeted for completion by the end of 2026.
• Interim Phase 2 ReSPECT-GBM data (Sept 30, 2024) showed a favorable safety profile, an average absorbed radiation dose of 300 Gy to the tumor, and a statistically significant reduction in tumor volume rate change for tumors receiving >100 Gy.
• Phase 1 of the ReSPECT-LM trial for leptomeningeal metastases was completed on February 26, 2025, with a recommended Phase 2 dose of 44.1 mCi, and one patient achieving a complete response.
• REYOBIQ treatment in ReSPECT-LM showed a consistent decrease in CSF tumor cell count and was well-tolerated, with interim results indicating a 50% increase in overall survival for LM patients.
• The FDA cleared the IND application for REYOBIQ for pediatric brain cancer (ReSPECT-PBC trial), with enrollment anticipated in the first half of 2026, supported by a $3.0 million DoD Award.
• The CNSide Test, a laboratory-developed test for CNS cancers, was re-introduced to the U.S. market in Q4 2025, with CLIA accreditation and payer coverage agreements with United Healthcare and Humana covering approximately 67 million lives.
• CNSide FORESEE trial data demonstrated doubled diagnostic sensitivity versus CSF cytology, influenced over 90% of clinical management decisions, and improved LM patient survival by approximately 50%.
• The FDA's final rule on LDT regulation (May 6, 2024) was vacated by a federal court on March 31, 2025, creating uncertainty regarding future LDT oversight.
• The company secured a $50.0 million equity line with Lincoln Park Capital Fund, LLC, having raised $19.6 million as of September 30, 2025, and an additional $1.9 million through October 29, 2025.
• A March 2025 private placement raised approximately $15.0 million gross proceeds, involving the issuance of common stock, pre-funded warrants, and Series A and B common warrants.

Sentiment

Score: 3

Explanation: The company is actively pursuing clinical development and has achieved positive interim results for its lead candidates and diagnostics, which are strong operational positives. However, significant financial challenges, including recurring losses, negative cash flow, substantial accumulated deficit, and ongoing Nasdaq listing compliance issues, create a high degree of financial risk and uncertainty about its ability to continue as a going concern. The need for continuous capital raises and the dilutive nature of recent financings further weigh on the sentiment.

Positives

• Completion of Phase 1 of the ReSPECT-GBM trial and ongoing enrollment in Phase 2, targeting full enrollment by end of 2026.
• Interim Phase 2 ReSPECT-GBM data showing a favorable safety profile, high absorbed radiation doses (average 300 Gy), and statistically significant tumor volume reduction for effective doses.
• Completion of Phase 1 of the ReSPECT-LM trial, identifying a recommended Phase 2 dose (44.1 mCi) and observing a complete response in one patient.
• Interim ReSPECT-LM results indicating REYOBIQ can increase overall survival by 50% and is well-tolerated with prompt and durable distribution.
• FDA Orphan Drug designation for REYOBIQ for LM in breast cancer (Nov 2023) and lung cancer (March 2025), and Fast Track designation for GBM (Sept 2020) and LM (Nov 2021).
• FDA clearance of the IND application for REYOBIQ for pediatric brain cancer (ReSPECT-PBC trial), with enrollment expected in H1 2026.
• Secured a $3.0 million DoD Award to support the expansion of the pediatric brain cancer clinical trial.
• Successful re-introduction of the CNSide Test to the U.S. market in Q4 2025, with CLIA accreditation and national payer coverage agreements (United Healthcare, Humana) covering ~67 million lives.
• CNSide FORESEE trial data demonstrating significantly enhanced diagnostic sensitivity (80% vs. 29% for CSF cytology) and influence on clinical management decisions in over 90% of LM cases, improving LM patient survival by ~50%.
• Identification of actionable mutations (e.g., HER2 amplification) by CNSide Test in 24% of breast cancer patients with HER2-negative primary tumors, informing treatment strategies.
• Establishment of a $50.0 million equity line with Lincoln Park Capital Fund, LLC, providing a source of capital, with $21.5 million raised through October 29, 2025.
• Regained compliance with Nasdaq's Minimum Stockholders Equity Requirement in March and August 2025.

Negatives

• Incurred net losses of $16.7 million for the nine months ended September 30, 2025, and $13.0 million for the year ended December 31, 2024.
• Accumulated deficit of $510.2 million as of September 30, 2025.
• Used $14.5 million in net cash for operating activities during the nine months ended September 30, 2025, and $10.6 million for the year ended December 31, 2024.
• Current working capital of $3.9 million as of September 30, 2025, and a working capital deficit of $10.292 million as of December 31, 2024, indicating insufficient liquidity for the next 12 months.
• Substantial doubt about the company's ability to continue as a going concern.
• Non-compliance with Nasdaq's Minimum Bid Requirement ($1.00 per share) since May 16, 2025, with a risk of delisting if compliance is not regained by May 11, 2026.
• Subject to a one-year Nasdaq panel monitoring period until August 22, 2026, for the Equity Standard, with no additional cure period if non-compliance recurs.
• FDA feedback for ReSPECT-LM indicated insufficient data to support CTCs as an intermediate clinical endpoint for accelerated approval, requiring a randomized trial for a marketing application.
• The company relies on sole source suppliers for critical raw materials, posing risks of supply interruptions, delays, and increased costs.
• The company has limited drug development, manufacturing, and commercialization experience, requiring reliance on third parties and potentially significant hiring.
• The company's current business strategy is high-risk due to intense competition, rapidly evolving technologies, and the uncertainty of commercial viability for product candidates and tests.

Risks

• Incurred losses since inception and expects significant net losses in the foreseeable future, with no guarantee of profitability.
• Uncertainties relating to the ability to fund operations for at least the next 12 months raise substantial doubt about the ability to continue as a going concern.
• Risk of delisting from Nasdaq for failure to comply with the Minimum Stockholders Equity Requirement, Minimum Bid Requirement, or other listing standards, which would harm stock liquidity and capital raising ability.
• Need for substantial additional funding to develop product candidates, conduct future operations, and repay outstanding debt obligations; inability to obtain funds may lead to delays or cessation of activities.
• Management has broad discretion over the use of offering proceeds, which may not be invested successfully.
• Purchasers of securities in this offering will incur immediate and substantial dilution in the book value of their common stock.
• No public market for pre-funded warrants, limiting their liquidity.
• Raising additional capital may cause further dilution to stockholders, restrict operations, or require relinquishing rights to technologies.
• Future success is dependent on successfully developing the nanomedicine platform and commercializing REYOBIQ and 188RNL-BAM; failure to do so would significantly harm the business.
• 188RNL-BAM will be regulated as a medical device, potentially resulting in additional regulatory and other risks, including lengthy and uncertain clearance/approval processes.
• Acquisition of the CNSide Portfolio may not be successful in terms of development, utilization, or monetization, and future regulatory changes for LDTs could adversely affect the business.
• Inability to successfully partner with other companies to commercialize product candidates could materially harm the business.
• Inability to obtain regulatory approvals for RNL product candidates, or other product candidates, would limit revenue generation.
• Failure of any party to a key collaboration, licensing, development, acquisition, or similar arrangement to perform obligations, or termination of such arrangements, could adversely affect the business.
• Breach of license agreements could lead to loss of critical license rights.
• Current business strategy is high-risk and may not be successful due to lack of prior regulatory experience, intense competition, and uncertainty of commercial viability.
• Reliance on government funding (CPRIT, DoD) may impose requirements that limit actions and subject the company to potential financial penalties, including repayment obligations.
• Product development is a lengthy, expensive, and uncertain process, with risks of additional costs, delays, or inability to complete development and commercialization.
• Pre-clinical studies and preliminary/interim clinical trial data are not necessarily predictive of future trial results.
• Limited resources may lead to pursuing less successful product candidates while forgoing more promising ones.
• Clinical trial results may fail to support regulatory approval.
• Failure of third-party CROs or CMOs to perform successfully could harm clinical development, regulatory approval, or commercialization.
• Significant adverse events from product candidates could prevent regulatory approval or market acceptance.
• Failure to achieve broad market acceptance for approved products, especially by physicians, would limit revenue.
• All potential applications of product candidates are investigational, subjecting the company to development and marketing risks.
• Inability to establish or sustain adequate coverage and reimbursement from third-party payors for future product candidates could diminish sales.
• Extensive and unpredictable regulation by FDA and other authorities, with potential for costly, time-consuming delays or denial of approvals.
• Ongoing regulatory obligations and review, with potential for significant expense and enforcement actions for non-compliance.
• Uncertain future regulatory processes for Laboratory Developed Tests (LDTs) may prevent obtaining required authorizations or introduce additional costs.
• Changing, new, and/or emerging government regulations, including healthcare legislative reform, may adversely affect the company.
• Compliance with federal regulations (e.g., Bayh-Dole Act) for government-funded intellectual property may limit exclusive rights and ability to contract with non-U.S. manufacturers.
• Orphan drug designation may not ensure market exclusivity.
• Interruption in supply from material sole source suppliers could harm the business.
• Strategic transactions (acquisitions, in-licensing) could impact liquidity, increase expenses, and distract management.
• Failure to maintain quality controls and compliance with manufacturing standards could lead to regulatory actions and delays.
• Inability to identify, hire, and/or retain key personnel, including CEO Marc Hedrick, could prevent business growth.
• Potential product liability exposure, with substantial liability if insurance coverage is inadequate.
• Failure to adequately protect health information could result in severe harm to reputation and significant liabilities.
• Non-compliance with environmental laws and regulations pertaining to hazardous and biological materials could expose the company to significant liabilities.
• Intellectual property protection may be insufficient, leading to infringement by third parties or costly litigation.
• Risk of claims that employees wrongfully used or disclosed trade secrets of former employers.
• Market price of common stock may be volatile and fluctuate significantly, resulting in substantial losses for stockholders.
• No active trading market for common stock may develop.
• Risk of securities litigation, which is costly and time-consuming.
• Future issuance of debt and equity securities may be senior to common stock, negatively affecting its value.
• Charter documents contain anti-takeover provisions.
• No intention to pay cash dividends on common stock in the foreseeable future.
• If securities/industry analysts cease coverage, change recommendations adversely, or expectations are not met, stock price and trading volume could decline.
• Increased information technology security threats and sophisticated computer crime pose risks to systems, networks, and products.

Future Outlook

The company expects to continue incurring net losses and negative cash flow from operating activities for at least the next twelve months, with recurring operating expenses at higher levels in 2025 due to clinical trials and development activities for nanomedicine product candidates. Research and development expenses are expected to increase during the remainder of 2025 as the ReSPECT-LM dose optimization trial commences and preparations for the CNSide Test launch continue. General and administrative expenditures are also expected to increase in 2025 due to the commercial launch of the CNSide Test, requiring increased administrative and sales headcount. The company anticipates beginning enrollment for its Phase 1 ReSPECT-PBC clinical trial in the first half of 2026. A manuscript detailing the CNSide FORESEE clinical trial methods and results is expected to be published in 2026. The company plans rapid expansion of CNSide Test availability into additional states in 2026 and expects to roll out expanded CNS testing capabilities over the next year. The CPRIT Contract is expected to provide grant revenue through August 2025, with amounts varying based on enrollment and regulatory interactions. The Houston Lease for new headquarters is expected to commence on or about November 1, 2026.

Management Comments

• Management has concluded that the correction to grant revenue in prior periods did not cause a material misstatement of our financial statements.
• Management has determined that the controls over application of appropriate accounting principles to significant and unusual grant revenue transactions are adequately designed and operating effectively, and concluded that the material weakness identified in the Quarterly Report on Form 10-Q for the quarter ended June 30, 2023 had been remediated.
• We intend to use the proceeds from this offering for working capital and general corporate purposes.
• We intend to continue to actively monitor the closing bid price of its common stock and will evaluate available options to regain compliance with the Minimum Bid Price Requirement. Specifically, we have confirmed to Nasdaq that, if necessary, it will implement a reverse stock split of our outstanding common stock to attempt to regain compliance.
• We expect that any such partners will provide regulatory and reimbursement/pricing expertise, sales and marketing resources, and other expertise and resources vital to the success of our product offerings in their territories.
• We expect that any such partnering arrangements will include upfront cash payments to us in return for the rights to develop, manufacture, and/or sell our product candidates in specified territories, as well as downstream revenue in the form of milestone payments and royalties.
• We believe our strategic investments in our analytical, development and manufacturing capabilities, including personnel with expertise from drug discovery through drug development, will allow us to advance our product candidates more quickly.
• We believe that the CNSide Test has the potential to complement its radiotherapeutic development programs by improving disease detection, patient stratification, and treatment monitoring in CNS cancers.

Industry Context

The company operates in the highly competitive and rapidly evolving life science industry, specifically targeting central nervous system (CNS) cancers with radiotherapeutics and diagnostics. This sector is characterized by significant R&D investment, lengthy regulatory processes, and intense competition from established pharmaceutical, biotechnology, and medical device companies. The company's focus on nanomedicine and targeted radiation therapies aims to address limitations of traditional treatments like external beam radiation, which often damage healthy tissue and have limited efficacy. The diagnostic segment, particularly Laboratory Developed Tests (LDTs), faces an uncertain regulatory landscape, as evidenced by the recent vacating of an FDA rule, which could impact commercialization pathways. The market for CNS cancers, including glioblastoma and leptomeningeal metastases, represents a significant unmet medical need, with current treatments offering marginal survival benefits. The company's strategy to leverage strategic partnerships for commercialization is common in this capital-intensive industry, where specialized expertise and resources are crucial for market penetration.

Comparison to Industry Standards

• REYOBIQ's potential to deliver radiation doses up to 20 times greater than commonly used External Beam Radiation Therapy (EBRT) while sparing normal tissue, contrasts with EBRT's limitations due to toxicity to surrounding healthy tissue.
• REYOBIQ's single, short, in-patient hospital visit for administration is a significant convenience advantage compared to EBRT's requirement for five days a week of out-patient visits for four to six weeks.
• In recurrent GBM, REYOBIQ's Phase 1 data showing a median overall survival of 17 months for patients receiving >100 Gy, compared to 6 months for those receiving <100 Gy, surpasses historical bevacizumab monotherapy outcomes.
• The CNSide Test demonstrated enhanced diagnostic sensitivity (80%) compared to the gold standard cerebrospinal fluid cytology (29%) in patients with LM, indicating a superior diagnostic capability.
• The CNSide Test's ability to influence clinical management decisions in over 90% of LM cases and improve survival of LM patients by approximately 50% suggests a significant clinical utility compared to existing diagnostic methods.

Management Changes

Corporate Governance

Legal Proceedings

• The company is subject to various claims and contingencies related to legal proceedings that arise in the ordinary course of business, but none are expected to result in a Material Adverse Effect.
• Two lawsuits challenging FDA's authority to regulate LDTs (one by the American Clinical Laboratory Association and one by the Association for Molecular Pathology) were filed in federal district courts in Texas in 2024 and consolidated. On March 31, 2025, the court issued an order vacating the FDA's final rule on LDTs, ruling that FDA lacks jurisdiction to regulate LDTs under the FDC Act.

Related Party Transactions

• In May 2024, certain directors and executive officers (Company Insiders) participated in the May 2024 Private Placement, purchasing 48,285 shares of common stock and accompanying warrants for an aggregate purchase price of $98,500.88.
• In January 2025, Marc H. Hedrick, M.D., the CEO and a director, provided a $140,000 loan to the company via a promissory note, which was fully repaid in March 2025. This transaction was approved by the Audit Committee.

Stakeholder Impact

• **Shareholders:** Potential for significant dilution from the current public offering and future capital raises. Risk of delisting from Nasdaq could harm liquidity and market price. Positive clinical trial results and commercialization efforts could increase shareholder value. Existing shareholders experienced substantial dilution from previous offerings.
• **Employees:** The company's ability to attract, retain, and motivate highly skilled personnel is critical for future success. Potential for reductions in employee base if additional funding is not secured. Stock-based compensation is a significant part of executive compensation.
• **Customers (Healthcare Providers & Patients):** Development of REYOBIQ and CNSide Test aims to provide improved detection and treatment options for CNS cancers, potentially enhancing patient outcomes and quality of life. Market acceptance by physicians and patients is crucial for commercial success.
• **Suppliers:** Reliance on sole source suppliers for raw materials creates supply chain risks, potentially impacting manufacturing and product development.
• **Creditors:** The company's ongoing need for additional financing and substantial doubt about its going concern status pose risks to creditors. Borrowings under credit facilities limit cash use and are due on demand.

Next Steps

• Complete full enrollment in Phase 2 of the ReSPECT-GBM trial by the end of 2026.
• Prepare a clinical study report and manuscript for the ReSPECT-LM Phase 1 trial.
• Continue enrollment in the ReSPECT-LM Multi-dose Phase 1/2 Study.
• Consider FDA feedback from the end of Phase 1 meeting for ReSPECT-LM and propose an updated protocol for the next study.
• Begin enrollment for the Phase 1 ReSPECT-PBC clinical trial in the first half of 2026.
• Further develop the CNSide Platform to support additional clinical applications.
• Expand CNSide Test availability into additional U.S. states in 2026.
• Roll out additional expanded CNS testing capabilities over the next year.
• Publish a manuscript detailing the CNSide FORESEE clinical trial methods and results in 2026.
• Continue to raise additional capital through equity offerings, debt financings, and potential collaboration/license agreements.
• Actively monitor common stock bid price and evaluate options, including a reverse stock split, to regain Nasdaq compliance by May 11, 2026.
• Manage compliance with the Nasdaq one-year panel monitoring period for the Equity Standard until August 22, 2026.
• Negotiate a commercial supply agreement with SpectronRx upon six months written notice before first commercial manufacturing needs.
• Continue to evaluate opportunities to integrate diagnostic insights from the CNSide platform with therapeutic development activities.

Key Dates

Recommendation

Plus Therapeutics presents a high-risk, high-reward profile. The company is in a precarious financial position, evidenced by substantial accumulated losses, negative cash flow, and a 'going concern' warning. Its Nasdaq listing is under threat due to a low bid price, which could necessitate a dilutive reverse stock split. These factors typically warrant a 'sell' or 'strong sell' recommendation. However, the company's clinical pipeline, particularly REYOBIQ, shows promising interim results in severe CNS cancers (GBM, LM, PBC), and the CNSide diagnostic platform has demonstrated significant clinical utility and market access agreements. These positive developments, if sustained and translated into regulatory approvals and commercial success, could fundamentally transform the company's outlook. The current offering aims to address immediate liquidity needs, but the long-term funding remains uncertain. Given the extreme financial risks balanced by potentially transformative clinical progress in areas of high unmet medical need, a 'hold' recommendation is appropriate for investors who are already exposed and can tolerate significant risk, allowing them to monitor the upcoming clinical milestones and Nasdaq compliance efforts. New investors should exercise extreme caution due to the high speculative nature and financial instability.

Keywords

Radiotherapeutics, CNS cancers, Glioblastoma, Leptomeningeal metastases, Pediatric brain cancer, REYOBIQ, Rhenium-186, Nanoliposomes, 188RNL-BAM, Rhenium-188, Biodegradable Alginate Microsphere, Liver cancer, CNSide Platform, CSF Tumor Cell Enumeration Test, LDTs, Clinical trials, Oncology, Biotechnology, Pharmaceuticals, SEC filing, Nasdaq listing, Capital raise, Warrants, Pre-funded units, Going concern, Medical device regulation, Orphan drug designation, Fast Track designation, CPRIT Grant, DoD Award, Lincoln Park Purchase Agreement